Related Experiment Video
Updated: Mar 24, 2026

Applying Stereotactic Injection Technique to Study Genetic Effects on Animal Behaviors
Published on: May 10, 2015
Isoform switching of steroid receptor co-activator-1 attenuates glucocorticoid-induced anxiogenic amygdala CRH
I Zalachoras1,2, S L Verhoeve1,2, L J Toonen3
1Division of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Abstract:
Maladaptive glucocorticoid effects contribute to stress-related psychopathology. The glucocorticoid receptor (GR) that mediates many of these effects uses multiple signaling pathways. We have tested the hypothesis that manipulation of downstream factors ('coregulators') can abrogate potentially maladaptive GR-mediated effects on fear-motivated behavior that are linked to corticotropin releasing hormone (CRH). For this purpose the expression ratio of two splice variants of steroid receptor coactivator-1 (SRC-1) was altered via antisense-mediated 'exon-skipping' in the central amygdala of the mouse brain. We observed that a change in splicing towards the repressive isoform SRC-1a strongly reduced glucocorticoid-induced responsiveness of Crh mRNA expression and increased methylation of the Crh promoter. The transcriptional GR target gene Fkbp5 remained responsive to glucocorticoids, indicating gene specificity of the effect. The shift of the SRC-1 splice variants altered glucocorticoid-dependent exploratory behavior and attenuated consolidation of contextual fear memory. In conclusion, our findings demonstrate that manipulation of GR signaling pathways related to the Crh gene can selectively diminish potentially maladaptive effects of glucocorticoids.
Insights
Altering steroid receptor coactivator-1 (SRC-1) splicing in mice reduced stress hormone effects on fear behavior. This manipulation selectively targets glucocorticoid receptor (GR) signaling, offering potential for stress-related psychopathology treatments.
Area of Science:
- Neuroscience
- Molecular Biology
- Endocrinology
Background:
- Maladaptive glucocorticoid effects are implicated in stress-related psychopathology.
- The glucocorticoid receptor (GR) mediates these effects through various signaling pathways.
- Corticotropin releasing hormone (CRH) is a key mediator in stress responses.
Purpose of the Study:
- To test if manipulating coregulators can mitigate maladaptive GR effects on fear behavior.
- To investigate the role of steroid receptor coactivator-1 (SRC-1) splice variants in GR signaling.
- To determine if altering SRC-1 splicing affects CRH gene expression and methylation.
Main Methods:
- Antisense-mediated exon-skipping was used to alter SRC-1 splice variants in the mouse central amygdala.
- CRH mRNA expression and promoter methylation were analyzed.
- Glucocorticoid responsiveness of the Fkbp5 gene was assessed.
- Glucocorticoid-dependent exploratory behavior and fear memory consolidation were evaluated.
Main Results:
- Shifting SRC-1 splicing towards the repressive SRC-1a isoform reduced glucocorticoid-induced CRH mRNA expression.
- Increased methylation of the Crh promoter was observed.
- The Fkbp5 gene remained responsive to glucocorticoids, showing gene-specific effects.
- Altered SRC-1 splicing affected exploratory behavior and attenuated fear memory consolidation.
Conclusions:
- Manipulation of GR signaling pathways, specifically targeting the CRH gene, can selectively reduce maladaptive glucocorticoid effects.
- Altering the ratio of SRC-1 splice variants offers a potential strategy to modulate stress responses.
- These findings highlight the role of coregulators in fine-tuning GR actions and their implications for psychopathology.
More Related Videos
08:29Biomarkers in an Animal Model for Revealing Neural, Hematologic, and Behavioral Correlates of PTSD
Published on: October 10, 2012
05:17BS3 Chemical Crosslinking Assay: Evaluating the Effect of Chronic Stress on Cell Surface GABAA Receptor Presentation in the Rodent Brain
Published on: May 26, 2023
Related Concept Videos
GPCR Desensitization
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Hypothalamic-Pituitary Axis
GPCRs Regulate Adenylyl Cylase Activity
The Two-State Receptor Model
The binding affinity of a drug determines its interaction with...